NASDAQ: TYRATyra Biosciences Inc Stock
$9.98+0.30 (+3.1%)
Updated May 20, 2025
TYRA Price
$9.98
Fair Value Price
$1.50
Market Cap
$530.72M
52 Week Low
$6.42
52 Week High
$29.60
P/E
-6.12x
P/B
1.64x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$96.44M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$73M
Beta
1.41
Next Earnings
May 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TYRA Overview
Tyra Biosciences Incorporated is a preclinical-stage biopharmaceutical company developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting other cancers. Tyra Biosciences was incorporated in 2018 and is headquartered in Carlsbad, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TYRA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TYRA
Ranked#265 of 454
Ranked#265 of 454
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $47.20 | A | |
| $8.30 | A | |
| $65.30 | A |
Be the first to know about important TYRA news, forecast changes, insider trades & much more!
TYRA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TYRA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TYRA ($9.98) is overvalued by 565.97% relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TYRA ($9.98) is not significantly undervalued (565.97%) relative to our estimate of its Fair Value price of $1.50 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TYRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TYRA due diligence checks available for Premium users.
Valuation
TYRA fair value
Fair Value of TYRA stock based on Discounted Cash Flow (DCF)
Price
$9.98
Fair Value
$1.50
Overvalued by
565.97%
TYRA ($9.98) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TYRA ($9.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TYRA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TYRA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.12x
Industry
-156.07x
Market
25.56x
TYRA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.64x
Industry
4.37x
TYRA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TYRA's financial health
Profit margin
Revenue
$0.0
Net Income
-$28.1M
Profit Margin
0%
TYRA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$343.5M
Liabilities
$19.9M
Debt to equity
0.06
TYRA's short-term assets ($324.57M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TYRA's short-term assets ($324.57M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TYRA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.5M
Investing
$32.0M
Financing
$2.2M
TYRA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TYRA vs Biotech Stocks
Tyra Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.